 The COVID-19 pandemic made Pfizer the most recognizable pharmaceutical company on the planet. But, COVID policies are dialing back and the future demand for COVID products is not clear. The Street expects Pfizers revenues to revert in the coming years as COVID vaccination rates slow and government contracts run out. The company expects 2023 to be a transition year. 